HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.

PTERIDINES is a unique journal dedicated to the study of pteridines and their implications in biochemistry and clinical research. Published by DE GRUYTER POLAND SP Z O O, this Open Access journal has been a vital resource since its inception in 1989, steadily evolving to include a diverse range of topics pertinent to molecular medicine and biochemistry. With its current classification in the Q4 quartile for Biochemistry, Clinical Biochemistry, and Molecular Medicine, PTERIDINES offers a platform for researchers and professionals seeking to disseminate and access groundbreaking findings. Although the journal has a modest Scopus ranking, it serves as an important outlet for both emerging and established scholars in the field, particularly those focusing on the biochemical roles of pteridines. Based in Germany, the journal invites contributions from around the globe, providing equitable access to all readers since 2018, making significant strides towards inclusive scientific discourse. As such, PTERIDINES is a valuable asset for anyone engaged in the exploration of pteridines and their multifaceted roles in health and disease.

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

Plasma is a leading open-access journal published by MDPI, devoted to the exploration and advancement of knowledge in the fields of engineering, physics, and materials science. Established in 2018, this journal provides a vital platform for researchers, professionals, and students to disseminate original findings and critical reviews related to plasma science, its applications, and its interdisciplinary aspects. With an E-ISSN of 2571-6182, Plasma actively promotes open access to ensure that research is widely accessible, reinforcing its commitment to accelerating scientific communication and collaboration across global communities. The journal enjoys respectable rankings in Scopus, with a notable position in Engineering, Physics and Astronomy, and Materials Science categories, making it an essential resource for those seeking to remain at the forefront of plasma research. Covering a range of topics until 2024, Plasma invites cutting-edge contributions that push the boundaries of understanding in this dynamic field.

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Turkish Journal of Plastic Surgery, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a pivotal platform for the dissemination of innovative research and clinical findings within the dynamic field of plastic surgery. With an ISSN of 1300-6878 and an E-ISSN of 2528-8644, this Open Access journal has been committed to making high-quality research accessible since 2018, fostering a broader reach and engagement among healthcare professionals, researchers, and students alike. Although its Scopus coverage has been discontinued since 2015, the journal maintains relevance via its niche in Medicine - Surgery, where it ranks 337 out of 422, placing it in the 20th percentile. Addressing a spectrum of topics from reconstructive techniques to aesthetic advancements, the Turkish Journal of Plastic Surgery not only contributes to the academic body of knowledge but also provides practical insights for clinical practices, thereby enhancing patient outcomes in the realm of plastic surgery.